From: Evaluating blinatumomab implementation in low- and middle-income countries: a study protocol
Primary data study participant group | Primary data inclusion criteria |
Local site physician champion | Submit an application for BHAP program enrollment |
Multidisciplinary local site pediatric oncology staff | Attend both 90-min synchronous training sessions or watch session recording online |
Local site implementation team | Will include a minimum of 2 physicians, 2 nurses, and 1 pharmacist at each LMIC site, who attended both training sessions and participated in frontline management of patients receiving blinatumomab in the inpatient setting |
Key stakeholders | Representatives from the pharmaceutical company actively involved in the drug donation program Representatives from St. Jude actively involved in the BHAP program LMIC site implementation team |
Secondary data study participant group | Secondary data inclusion criteria |
Patients | Satisfy BHAP program enrollment criteria to receive blinatumomab, parental consent to receive blinatumomab (obtained by a local physician), and initiate blinatumomab infusion |